Amgen-Sandoz analysis: Come patent dancing at the Supreme Court
Natalie Rahhal analyses the issues at stake when the US Supreme Court hears the biosimilars dispute between Sandoz and Amgen later this year
The Supreme Court granted cert for the cross-petitions of Sandoz and Amgen on January 13, and will later this year will hear its first biosimilars case since the Biologics Price Competition and Innovation Act (BPCIA) came into effect.
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.